SRNE vs. NSTG, KPRX, IMNN, CDIO, ERNA, PHXM, RDHL, TNXP, KA, and OBSV
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include NanoString Technologies (NSTG), Kiora Pharmaceuticals (KPRX), Imunon (IMNN), Cardio Diagnostics (CDIO), Eterna Therapeutics (ERNA), PHAXIAM Therapeutics (PHXM), RedHill Biopharma (RDHL), Tonix Pharmaceuticals (TNXP), Kineta (KA), and ObsEva (OBSV). These companies are all part of the "medical" sector.
Sorrento Therapeutics (NASDAQ:SRNE) and NanoString Technologies (NASDAQ:NSTG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Sorrento Therapeutics has a net margin of 0.00% compared to NanoString Technologies' net margin of -102.44%. Sorrento Therapeutics' return on equity of 0.00% beat NanoString Technologies' return on equity.
NanoString Technologies has a consensus target price of $7.63, indicating a potential upside of ∞. Given NanoString Technologies' higher probable upside, analysts clearly believe NanoString Technologies is more favorable than Sorrento Therapeutics.
0.0% of Sorrento Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 3.1% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
NanoString Technologies has higher revenue and earnings than Sorrento Therapeutics.
In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled NanoString Technologies'average media sentiment score.
Sorrento Therapeutics received 106 more outperform votes than NanoString Technologies when rated by MarketBeat users. Likewise, 70.20% of users gave Sorrento Therapeutics an outperform vote while only 62.61% of users gave NanoString Technologies an outperform vote.
Sorrento Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Summary
Sorrento Therapeutics beats NanoString Technologies on 7 of the 12 factors compared between the two stocks.
Get Sorrento Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sorrento Therapeutics Competitors List
Related Companies and Tools
